Innovative drug concept Hong Kong stocks increase, Ge Li Pharmaceutical rises more than 17%

Some innovative pharmaceutical stocks in Hong Kong saw an increase in the afternoon. As of the publication, Gilead Sciences-B rose more than 17%, Livzon Pharmaceutical-B rose more than 14%, and Akeso-B rose more than 13%. On the news front, the eleventh batch of national centralized drug procurement work has been launched recently, and this procurement will adhere to the principles of "stabilizing clinical practices, ensuring quality, preventing collusion and avoiding redundancy". Previously, the National Medical Insurance Administration added innovative drugs to the commercial insurance drug list, establishing a dual-track payment system of "basic medical insurance covers basic needs + commercial insurance covers high-value innovative drugs".